|
|
|
|
NeoStem and Invetech Announce Agreement
to Develop Closed Processing System
for Cell Therapy Manufacturing
New System Will Support Commercial-Scale Manufacturing
of Cell Therapies and Other Patient-Specific Products
New York, NY and San Diego, CA Jan. 12, 2015 -- NeoStem, Inc. (Nasdaq:NBS), a leader in the development and manufacturing of cell therapy products and regenerative medicine, and Invetech Pty Ltd ("Invetech"), a global leader in instrument development, custom automation and contract manufacturing, today announced an agreement for the development of a new closed processing system (the "System") for cell therapy manufacturing. Under the agreement, Invetech will provide system design and engineering development and NeoStem will develop applications for performing closed cell processing manipulations such as separation. The agreement envisions NeoStem as the commercial supplier of the System which would constitute its first branded entry into the cell therapy tools market.
The System will be applicable to a range of cell therapy processes in development and commercialization stages, and will consist of an instrumentation platform, disposable flow path, and operating and application software for automated execution of user-selected protocols. The System will provide a flexible small scale process suitable for GMP manufacturing of autologous and other patient-specific products where small scale is full scale, while also supporting efficient development of processes at lower cost prior to transitioning to scaled volumes.
"We are pleased to be partnering with Invetech on the development of a new technology specifically designed to meet the needs of our clients as their cell therapy products progress through clinical trials on a path towards commercialization," said Robert A. Preti, Ph.D., president of PCT, and chief scientific officer of NeoStem. PCT will carry out the work and is a wholly-owned subsidiary of NeoStem.. "By combining PCT's more than 15 years of process development and manufacturing experience with Invetech's industry leading automated processing device expertise, we hope to produce and potentially market a system that would deliver significant cost of goods, quality, and scaling benefits over existing manual, cleanroom-based processing strategies."
"Working with NeoStem to create equipment that will deliver services to companies in the emerging cell therapy industry is exciting and satisfying," said Richard Grant, global vice president, cell therapy division of Invetech. "Our team shares a common passion with NeoStem to grow the cell therapy industry by developing new technology to support successful product development and commercialization."
"NeoStem's Engineering and Innovation Center (EIC) is one of the first dedicated centers responding directly to the major challenges that are facing the manufacturers of cell based therapeutics," said Brian Hampson, vice president, manufacturing development and engineering. "If ultimately commercialized, the sale of disposables associated with the System, especially for patient-specific therapies where one disposable set is used per patient, could potentially become a meaningful revenue area for NeoStem."
About NeoStem
NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The combination of a rich therapeutics pipeline and externally recognized in-house manufacturing expertise has created an organization with unique capabilities for cost effective and accelerated product development. www.neostem.com
About Invetech
Invetech has been creating breakthrough products and custom automation systems for more than 30 years. With experience drawn from more than 5,000 projects globally, Invetech partners with global leaders in industry to deliver product design and development, contract manufacturing, and custom automation services. The company has experience in a broad range of market sectors including laboratory diagnostics, point of care diagnostics, life sciences, cell therapy, industrial and consumer products. With active projects in North America, Europe, and Asia Pacific, Invetech is well positioned to service clients ranging from startups to established multinationals. www.invetech.us
Forward-Looking Statements for NeoStem, Inc.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, the Company's ability to develop and grow its business, the successful development of cellular therapies with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's Targeted Immunotherapy Program, Ischemic Repair Program , Immune Modulation Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry, and the performance and planned expansion of the Company's contract development and manufacturing business as well as its efforts to expand its capabilities into the cell therapy tools market. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 13, 2014, the Company's Current Report on Form 8-K filed with the SEC on May 8, 2014 and in the Company's other periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside of its control.
Investor Relations Contact:
Stanley Wunderlich
Consulting for Strategic Growth 1 Ltd.
Tel: 800-625-2236 ext. 7770
Email: info@cfsg1.com
|
|
|
About SWI
SWI is a leading edge information marketing service with a highly frequented web site www.stockwatchindex.com and its "Rise Above The Noise" newsletter. The Newsletter informs you about new and promising discoveries. The periodical "Portfolio Performance Report" reports on the performance of the stocks that we have purchased and are holding in the SWI portfolio. The weekly "SWI QuickPicks" Ratings Report keeps you informed about newly initiated stocks and potential upgrades and downgrades in the QuickPicks section on our StockWatchIndex website. We do not necessarily hold positions in any of these stocks. SWI QuickPicks represent the consolidated opinions of carefully selected financial analyst blogs and opinions of Wall Street firms that we respect and frequently sample. You can conveniently follow the live links for each stock on http://www.stockwatchindex.com/swi-quickpicks/ for more detail. Please do not miss the wealth of frequently updated news, research reports and other valuable information elsewhere on SWI, especially for the stocks on our WatchIndex page. Watch a full range of CEO and analyst interviews on our Strategic Partner site www.wideworldofstocks.com.
SWI Investment Criteria
We do not necessarily present stocks for "day-trading-profits", although following our news could create the opportunity to do so. Our recommendations are never solely based on the day's or week's performance, or on an anticipated awareness campaign. They are based on current and past performance, analysis of the current and projected financial position, as well as the expectation that we have for the general performance of the Company going forward. Actual results always depend on the timely implementation of the company's business plan. SWI picks companies at an early stage of their development that it (and other credible analysts) believe have a solid core business model and good potential for success. This service for our subscribers is meant to convey a "quick" reflection of the market mood for certain stocks, which may inspire you to depart on your own research. We disclose in the individual stock and/or analyst reports , if any of the companies or third parties may have compensated us for distributing the information about their companies. Do not solely rely on the opinions expressed in this publication, always talk to your personal investment adviser before making an investment decision. Be aware that investing into penny stocks represents a high risk investment and you can potentially loose your entire investment.
Good luck and please pass this newsletter on to a friend
to continue building our community.
|
|
|
StockWatchIndex (SWI) is not a registered investment adviser and makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in the publications for its Stock Watch List or on its web sites. The provided information is not to be construed as personal financial advice, or a solicitation to buy or sell stock. Some information has been generated by what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or warrant any results from use of the information. We have contracted with (MEDL) and some of the other companies we represent as public relations consultants to keep the market and especially our subscribers informed about the company and are being compensated in cash and stock options. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in its Stock Watch List or on its web sites. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. StockWatchIndex expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. The included information is subject to change without notice..
|
|
Copyright © 2015 StockWatchIndex, LLC, All rights reserved.
unsubscribe from this list update subscription preferences
 |
|
|
|
|
|
|
|
|
|
